Here, HMGB2 blockade represents a promising strategy to increase the curative efficiency of the anti–PD-1 therapy in both HCC and colorectal cancer, attributed to augmented IFN-γ+ CD8+ T cell infiltration. Here, PDCD1 is linked to hepatocellular carcinoma.